SEATTLE, WA (November 1, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today CEO Steven Reed will give a corporate presentation on Nov. 8, 3 pm, Fourth Floor, (Adams) at the BioFuture Investor Conference at the Lotte Palace Hotel in New York City.

Dr. Reed will update investors on HDT’s pipeline and products which span multiple immunotherapy mechanisms with an emphasis on developing cost effectives disease vaccines to prevent infectious disease across the globe.

HDT Bio’s technology is the basis for GEMCOVAC, a COVID-19 vaccine and the first saRNA vaccine authorized for use in humans.

HDT also recently received a collaborative agreement with the National Cancer Institute to co-develop saRNA vaccines to prevent and treat multiple cancers; a US Army grant to develop a nasal spray to protect military personnel from deadly viruses; and an SBIR grant to develop RNA vaccines and therapeutics for Enterovirus D68, a respiratory virus in children.


BioFuture, produced by Demy-Colton, is a conference convening future-focused healthcare thinkers, top investors, stakeholders and cutting-edge companies to “Reimagine the Future of Therapeutics”. BioFuture will be held in-person in New York City on November 7-9, 2022, at the Lotte Palace Hotel, with a virtual access option for digital partnering and recorded content on November 14-16.


HDT Bio is a Seattle-based, clinical-stage biopharmaceutical development company. With core technology and expertise in nucleic acid formulation, the company develops products that seek to harness host-directed immune responses. HDT Bio’s work focuses on infectious disease and oncology vaccines and therapeutics through early-stage collaborations with partners worldwide. The company’s vaccine platform, repRNA/LION™, combines formulation and adjuvant ingredients to stabilize and deliver self-amplifying RNA to the immune system to stimulate responses. HDT Bio’s COVID19 vaccine is the first self-amplifying RNA vaccine to ever receive a regulatory authorization.